Open an account

Prenetics Global

PRE · NASDAQ

$18.63−$0.39 (−2.05%)TodayMarket closed ·
Prev close $19.02

About PRE

Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.

Employees
285
Headquarters
Hong Kong
Listed
Jul 6, 2021
Sector
Health Care
Industry
Health Care Providers & Services
Website
ir.prenetics.com

PRE key statistics

Market cap
319.38M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
196.03K
Volume
92.90K
Open price
$19.04
High today
$19.88
Low today
$18.55
52 Week high
$27.24
52 Week low
$11.37

Prenetics Global (PRE) at a glance

Prenetics Global (PRE) last traded at $18.63, with a market cap of 319.38M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $18.55 and $19.88. The current price is 0.4% above the day's low and 6.3% below its high.

Volume so far is 92.90K shares, below the average of 196.03K shares a day.

Over the past year Prenetics Global has ranged from $11.37 to $27.24, and now sits 46% of the way up that range.

Prenetics Global met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.53 per share against an estimate of -$0.7191.

The average analyst price target is $36.57, 96.3% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $36.57
Low
$30.30
Now
$18.63
High
$42.00

PRE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 11.4% on average.

  1. Q3 FY24: reported -$0.84 per share against an estimate of -$0.8686
  2. Q4 FY24: reported -$1.28 per share against an estimate of -$0.7272
  3. Q1 FY25: reported -$0.80 per share against an estimate of -$0.7777
  4. Q2 FY25: reported -$0.94 per share against an estimate of -$0.7171
  5. Q3 FY25: reported -$0.53 per share against an estimate of -$0.5555
  6. Q4 FY25: reported -$1.75 per share against an estimate of -$0.3468
  7. Q1 FY26: reported -$1.61 per share against an estimate of -$1.11
  8. Q2 FY26: reported -$0.53 per share against an estimate of -$0.7191

PRE news

  • Prenetics Global Q2 2026 Earnings Call: Complete Transcript

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Avi Kapoor

    Nasdaq Surges Over 1%; US Durable Goods Orders Fall In December

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.